RPL29 involved in several pathways and played different roles in them. We selected most pathways RPL29 participated on our site, such as Ribosome, which may be useful for your reference. Also, other proteins which involved in the same pathway with RPL29 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
| Pathway Name |
Pathway Related Protein |
| Ribosome |
RPL11; MRPL9; RPL37; RPL28; RPL10; RPS15A; MRPL10; MRPL23; MRPL18; RPS2 |
RPL29 has several biochemical functions, for example, RNA binding, heparin binding, poly(A) RNA binding. Some of the functions are cooperated with other proteins, some of the functions could acted by RPL29 itself. We selected most functions RPL29 had, and list some proteins which have the same functions with RPL29. You can find most of the proteins on our site.
| Function |
Related Protein |
| RNA binding |
RPL5; RPS3A; GRB7; CSDC2; U2AF2A; THUMPD2; WRAP53; SAMHD1; RPS3; CWC22 |
| heparin binding |
FGF10; ECM2; LIPH; FGFR4; APP; COL20A1; SLIT1B; UBE4A; ADAMTSL5; KAL1 |
| poly(A) RNA binding |
PARN; GSPT2; RBMS2; FKBP3; ZNF638; PCBP3; DDX54; STIP1; ELAC2; PURB |
| structural constituent of ribosome |
RPS14; RPS13; MRPL49; RPS26; RPSA; RPL26L1; RPS9; RPS29; MRP63; RPL36 |
RPL29 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with RPL29 here. Most of them are supplied by our site. Hope this information will be useful for your research of RPL29.
ESR2; RTCA; MAGEB2; PSTPIP1; EIF1B; TIMP2; HLA-B; VHL; PINX1; DDX56; CHD3; UBE2O; SYBU; Smad6; FN1; ESR1; NPM1; RPL10; p27958-pro_0000037566
Miyake, Y; Matsushita, H; et al. Anti-60S ribosomal protein L29 antibody; new anti-cancer agent discovered from human sera. EUROPEAN JOURNAL OF CANCER 49:S136-S136(2013).
Miyake, Y; Matsushita, H; et al. Anti-60S ribosomal protein L29 antibody: New anticancer agent discovered from human sera.. JOURNAL OF CLINICAL ONCOLOGY 31:-(2013).
